Day One Biopharmaceuticals Executive Compensation (FY24)
DAWN · Executive and director compensation, fiscal 2022 to 2024
The Day One Biopharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (DEF 14A): April 11, 2025
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
185 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jeremy Bender: $6,913,959 → $6,560,577 (5.1% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Day One Biopharmaceuticals' chief executive and what were they paid?
Jeremy Bender, Chief Executive Officer and President, received $6,560,577 in total compensation for fiscal 2024. Compared with the $6,913,959 reported for fiscal 2023, Bender's total was 5.1% lower.
What is Day One Biopharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 17:1 for fiscal 2024, against median employee compensation of $389,481.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jeremy Bender Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Charles York Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Samuel Blackman Co-Founder and Head of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jeremy Bender Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Charles York Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Adam Dubow General Counsel, Chief Compliance Officer and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | — not reconciled |
Samuel Blackman Co-Founder and Head of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jeremy Bender Chief Executive Officer and President | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Charles York Chief Operating Officer and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Samuel Blackman Co-Founder and Head of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Adam Dubow General Counsel, Chief Compliance Officer and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Adam Dubow | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Adam Dubow | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Charles N. York II | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Charles N. York II | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jeremy Bender | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jeremy Bender | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Samuel Blackman | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Samuel Blackman | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Samuel Blackman | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Jeremy Bender | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Charles York | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Adam Dubow | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
William Grossman | ◇ | — | ◇ | — | — | — | ◇ |
Habib Dable | ◇ | — | ◇ | — | — | — | ◇ |
Garry Nicholson Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Natalie Holles | ◇ | — | ◇ | — | — | — | ◇ |
John Josey | ◇ | — | ◇ | — | — | — | ◇ |
Scott Garland | ◇ | — | ◇ | — | — | — | ◇ |
Michael Gladstone | ◇ | — | ◇ | — | — | — | ◇ |
Daniel Becker | ◇ | — | — | — | — | — | ◇ |
Jeremy Bender and Saira Ramasastry served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Day One Biopharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
185 figures on this page, cited to the filing that reported them.
185 cited to the filing
Documents cited
- 0001140361-25-013462CEO Pay Ratio · Director Compensation · ELECTION OF DIRECTORS · Grants of Plan-Based Awards · and 4 more sections
- 0001140361-24-018305Summary Compensation Table
- 0001140361-23-0214872022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Day One Biopharmaceuticals executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/DAWN (accessed 2026).
Short form: data: Velarion
The Day One Biopharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Day One Biopharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}